BCA
SLNO

Bray Capital Advisors’s Soleno Therapeutics SLNO Stock Holding History

Bray Capital Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-133
Closed – – 278
2022
Q1 		$0 Hold
133
– – ﹤0.01% 286
2021
Q4 		$1K Hold
133
– – ﹤0.01% 275
2021
Q3 		$2K Buy
+133
New +$1.85K ﹤0.01% 266

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bray Capital Advisors's SLNO Position: Q2 2022 in Review

Bray Capital Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2022, closing a stake of 133 shares.

Bray Capital Advisors first reported a position in SLNO in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 40 funds tracked by Wall St. Rank hold SLNO as of Q2 2022.

  • Bray Capital Advisors reported no remaining Soleno Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bray Capital Advisors sold 133 Soleno Therapeutics shares in Q2 2022.
  • Bray Capital Advisors first reported a position in Soleno Therapeutics in Q3 2021 and held it in 3 quarters.
  • Bray Capital Advisors's Soleno Therapeutics position peaked at $2K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2022.

Based on Bray Capital Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.